Article
Transposon Mutagenesis Reveals RBMS3 as a Promoter of Malignant Progression of BRAF <sup>V600E</sup> -Driven Lung Tumorigenesis
2022-02-28
Abstract excerpt
<h4>ABSTRACT</h4> Mutationally-activated BRAF V600E is detected in ~2% of all human non-small cell lung cancers (NSCLC), and serves as a predictive biomarker for treatment of patients with FDA-approved pathway-targeted therapies that inhibit signaling by the BRAF V600E oncoprotein kinase. In genetically engineered mouse (GEM) models, expression of BRAF V600E in alveolar type 2 (AT2) pneumocytes initiates the d...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3f2880f0-6f31-5ae5-b959-aa94745b0402
- DOI
- 10.1101/2022.02.28.482366
